CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer
CTDNA Response Adaptive Immuno-Chemotherapy in Non-Small Cell Lung Cancer
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
SLIDE-HCC: Phase II trial of STRIDE (durvalumab + tremelimumab) + lenvatinib vs STRIDE in patients with unresectable hepatocellular carcinoma
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
Docetaxel and Hormone Treatment compared to Hormone Treatment alone in people with Metastatic Castration Sensitive Prostate Cancer and Less than Optimal PSA Response (TRIPLE-SWITCH)
The CCTG Connection will be on hiatus until the Fall.
CCTG is very pleased to announce that Dr. Tim Whelan is the 2020 recipient of the CCTG Founder's Award - Dr. Joseph Pater Excellence in Clinical Trials Research.
This award honours an investigator whose leadership and body of work has contributed to significant advances in the understanding, diagnosis, treatment, cure, and prevention of cancer. This individual's research has provided techniques, information or concepts that will direct the future of the oncology research community and CCTG.
CCTG is pleased to announce that the 2020 CCTG IND Team Award has been awarded to the BCCA Vancouver Centre IND.234 trial team based on the centre's accrual metrics both overall and for this past year, local activation timelines, and compliance metrics.
The team members include: Kim Chi, Manahil Sadiq, Julita Sienkiewicz, and Wendy Won.
CCTG is very pleased to announce that Dr. Dan Renouf has been awarded the CCTG Dr. Ralph Meyer Phase III Program Young Investigator Award.
This award honours young investigators who have contributed significantly on CCTG phase III projects with CCTG Disease Site Committees, Endpoint Committees, or Working Groups.
“I’m very honored to both be nominated for and to receive this award. The mentorship provided to me by many members within CCTG is very much appreciated," says Dr. Renouf.
CCTG is pleased to announce that the 2020 CCTG Phase III Team Award for Intergroup-Led trials has been awarded to the Princess Margaret Cancer Centre CE.8 trial team based on the centre's accrual metrics both overall and for this past year, local activation timelines, and compliance metrics.
CCTG is very proud to announce that Dr. Lillian Siu, Princess Margaret Cancer Centre, has been chosen as the recipient of the 2020 International Women Who Conquer Cancer Mentorship Award. Dr. Siu is the director of the Phase I Program, co-director of the Bras and Family Drug Development Program, and clinical lead for the Tumor Immunotherapy Program at Princess Margaret and is Co-Chair of CCTG's Head and Neck Site Committee. She also holds the BMO Chair in Precision Genomics.
CCTG is very pleased to announce that Dr. Sara Taylor is the 2020 recipient of the Dr. Elizabeth Eisenhauer Early Drug Development Young Investigator Award.
This award honours young investigators who have participated in the Investigational New Drug (IND) Program and have significantly contributed to IND trial conduct within their institution. Individuals are nominated by their colleagues and the IND Director/Executive Committee to determine the awardee.
CCTG is pleased to announce that the 2020 CCTG Phase III Team Award for Intergroup-Led trials has been awarded to the Saskatoon Cancer Centre MAC.21 trial team based on the centre's accrual metrics both overall and for this past year, local activation timelines, and compliance metrics.
The team members include: Nayyer Iqbal, Osama Ahmed, Shahid Ahmed, Tehmina Asif, Kamal Haider, Amer Sami, Mita Manna, Andrea Gallivan, Dominique Wagner, Jolene Hicks.
